In contrast to our findings, the PRACTICAL consortium investigated a pooled cohort of germline ATM mutation carriers, concluding that although they were associated with younger age of prostate cancer onset, variants did not conclusively predispose carriers to more aggressive prostate cancer phenotypes [10]. The gene discussed is ATM; the disease is prostate cancer.